Thursday May 18, 11:19 am Eastern Time
Company Press Release
SOURCE: New Brunswick Scientific Co., Inc.
New Brunswick Scientific Appoints James Orcutt Life
Sciences President
EDISON, N.J., May 18 /PRNewswire/ -- New Brunswick Scientific Co., Inc. (Nasdaq: NBSC - news), today announced
that James T. Orcutt has been named to the newly created position of President, Life Sciences Operations.
Mr. Orcutt, 43, brings more than 20 years of comprehensive operations experience and business development to the
Company. Most recently, he was Senior Vice President of Sales, Marketing and Development for Boekel Industries, with
responsibilities for all sales and marketing activities as well as revamping its new-product development process. Boekel is a
global manufacturer and supplier of life sciences and general laboratory equipment. Before joining Boekel, Mr. Orcutt spent 12
years with Barnstead/Thermolyne Corporation, where he rose rapidly through a succession of progressively responsible
positions until his appointment in 1990 as Marketing Manager of Barnstead's $24-million ultrapure water business. Previously,
he was a project engineer for Herzog-Hart Corporation (1981-83) and a field engineer with KVB, Inc. (1979-81). Mr. Orcutt
earned his Bachelor of Science degree in Chemical Engineering from Worcester Polytechnic Institute.
New Brunswick Scientific's co-founder and Chairman David Freedman, commented: ``Jim possesses unique, industry-specific
talents that should serve to promote innovation, enhance efficiencies and stimulate growth in our core laboratory equipment and
instrumentation business. His combined managerial and technological expertise provides an excellent fit with our needs,
particularly with regard to our current emphasis on product development and acquisition opportunities, and we are very pleased
to welcome him as part of our management team.''
New Brunswick Scientific Co., Inc., designs and manufactures a wide variety of research equipment and scientific instruments
for the life sciences. The Company, through DGI BioTechnologies, its majority-owned drug-lead-discovery operation, has
developed and patented a proprietary process that is expected to result in the discovery of novel therapeutics by generating
biologically active drug leads for known pharmaceutical targets.
SOURCE: New Brunswick Scientific Co., Inc. |
